Rationale: The airway epithelium serves as the first protective
barrier against cigarette smoke (CS), which is a major cause of chronic
lung disease (CLD). While transient and persistent transcriptomic
changes in the bronchial epithelium as a result of CS exposure have been
described, proteomic studies are lacking in this context. Objective:
To uncover CS-induced effects on the human airway proteome and identify
the cellular source of transient and persistent changes. Methods:
Label-free tandem mass spectrometry-based proteomics data of
bronchoalveolar lavage fluid (BALF) from a CLD patient cohort mainly
composed of interstitial lung disease (ILD) patients (n=124; 16
idiopathic pulmonary fibrosis (IPF), 79 non-IPF ILD, 29 non-ILD1)
was analyzed in respect of patients' smoking history (ex-, active- and
never-smokers). Results were compared to the proteome of chronically
CS-exposed primary human bronchial epithelial cells (phBECs) relative to
unexposed controls. Cellular sources of persistent protein changes were
explored using immunofluorescent stainings of human lung tissue and
whole lung single cell RNA-Seq analysis. Results: Smoking was
associated with transient (up in active but lost in ex-smokers) and
persistent (up in active and sustained in ex-smokers) protein changes in
the BALF samples. We observed an overlap between CS-induced protein
changes in phBECs and transient changes in BALF. Proteins associated
with the persistent response primarily localized to macrophages as well
as to basal and ciliated cells, but not to secretory cells, in the
bronchial epithelium. Conclusion: CS triggers both transient and
persistent protein changes in BALF of CLD patients. While the transient
expression changes likely originate from the bronchial epithelium,
persistent changes stem from both bronchial epithelial cells and
macrophages. The results warrant further investigation into the
relevance of these changes for onset and progression of CS-associated
CLD. 1Mayr CH, et al. Integrative analysis of cell state changes in lung fibrosis with peripheral protein biomarkers. EMBO Mol Med 13: e12871, 2021.